Short answer
Apogee Therapeutics, Inc. (APGE) filed an 8-K current report with the SEC on June 22, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Exclusive worldwide IL-31R antibody license expands Apogee’s pipeline into a new target with sublicensing rights.
Apogee Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Exclusive worldwide IL-31R antibody license expands Apogee’s pipeline into a new target with sublicensing rights
- Up to $23.25M in development, clinical and regulatory milestones for the first qualifying product
- $5.25M milestone triggered by first patient dosing in a Phase I trial
- Low-single-digit royalties on net sales, lasting at least 12 years after first commercial sale or through patent expiration
- Optional manufacturing activities could add $1.3M–$2.0M in fees; Apogee bears development and commercialization costs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Apogee Therapeutics, Inc. 8-K filings
Get the next APGE 8-K as it lands
Follow APGE for push alerts, or ask the research agent what this filing means.